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Summary 
Pfs25 is a sexual stage antigen of Plasmodiumfakiparum  that is expressed on the surface of zygote 
and ookinete forms of the parasite. Monoclonal antibodies directed against native Pfs25 can block 
completely the development ofP. fakiparum oocysts in the midgut of the mosquito vector. Thus, 
this 25-kD protein is a potential vaccine candidate for eliciting transmission-blocking immunity 
in inhabitants of  malaria endemic regions. We have synthesized, by secretion from yeast, a polypeptide 
analogue of Pfs25 that reacts with conformation-dependent monoclonal antibodies, and elicits 
transmission-blocking antibodies when used to immunize mice and monkeys in conjunction with 
a muramyl tripeptide adjuvant. Our results suggest the further evaluation of recombinant DNAo 
derived Pfs25  in  transmission-blocking vaccination studies in humans. 
T 
he increasing resistance to chemotherapy of the parasites 
responsible for human malaria has reaffirmed the require- 
ment for an effective malaria vaccine. Subunit vaccine strate- 
gies using either peptide synthesis or recombinant DNA tech- 
nologies have been focused primarily on the immunization 
of the human host against asexual forms of the parasite.  For 
example, well-studied vaccination approaches have targeted 
the induction of neutralizing responses against the sporozoite 
form of the parasite that is injected by the mosquito vector 
during a blood meal. Also, merozoite and erythrocytic-stage 
antigens have been considered as immunogens for the sup- 
pression of parasitemia in susceptible individuals. An alter- 
native approach for the control of endemic malaria in de- 
vdoping countries is that of transmission-blocking  vaccination. 
Here, it has been proposed that such a strategy could prevent 
the transmission of viable sexual forms of the parasite from 
humans to mosquitoes. Foremost among transmission-block- 
ing vaccine candidates is the Plasmodium fakiparum  surface 
protein Pfs25.  This 25-kD polypeptide is expressed on the 
surface of zygote and ookinete forms of the parasite as they 
develop in the midgut of the mosquito vector (1). mAbs to 
Pfs25  have been shown to block fully the development of 
sexual stages of the parasite (1, 2), and vaccinia virus recom- 
binants that express Pfs25 can induce transmission-blocking 
antibodies in MHC-disparate congenic mice (3). Such studies 
have suggested that the production of large quantities of syn- 
thetic Pfs25 peptides, or recombinant Pfs25 protein, together 
with recreation of the appropriate conformation orB cell epi- 
topes for immunological activity in vivo are required for the 
development of Pfs25  as a human vaccine.  Here, we show 
that an analogue of Pfs25, synthesized by secretion from yeast, 
reacts with conformation-dependent mAbs,  and can elicit 
transmission-blocking  antibodies when used to immunize mice 
and monkeys in conjunction with a muramyl tripeptide (MTP) 
adjuvant. 
Materials and Methods 
DNA Manipulations.  Oligonucleotides were synthesized  by the 
phosphoramidite method using DNA synthesizers (380]3; Applied 
Biosystems, Inc., Foster City, CA). Gene assembly  and site-directed 
mutagenesis were performed using standard procedures (4). 
Yeast Expression and Protein Purification.  The synthetic Pfs25 
genes were cloned into the yeast vector pBS24 (5) and the resulting 
plasmids were used to transform yeast strain AB110 (6). Pfs25-B 
was purified from yeast supernatants subsequent to removal  of  yeast 
cells by continuous  flow centrifugation.  Supernatants were con- 
centrated and desalted by tangential flow ultrafiltration over a 5-kD 
membrane. Initial purification was achieved  by ion-exchange chro- 
matography on Fast Flow Q resin (Pharmacia Fine Chemicals, Pis- 
cataway, NJ), equilibrated with 10 mM Tris/HC1, pH 8.0, 1 mM 
EDTA, using a 0-0.3  M NaC1 gradient for elution. The elution 
profile was monitored at A2s0, and the major peak was confirmed 
as Pfs25-B by SDS-PAGE. Fractions that contained Pfs25-B were 
pooled, concentrated by ultrafiltration to 10--20 mg/ml, and sepa- 
rated by gel filtration on S-100 HR Sepharose (Pharmacia Fine 
Chemicals). The column was developed  in 2 x  PBS and monitored 
in an identical manner to the ion-exchange purification step. The 
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material lyophylized and stored at 4~ 
Immunizations.  In the Freund's adjuvant group, mice  were im- 
munized three times at 3-wk intervals with 50 #g of Pfs25-B in 
a final volume of 100/~1, as described previously (7). In the MF59 
adjuvant groups, mice were immunized, using the same protocol 
with Pfs25-B, falc 2.3 (7), hEGF (8), or hSOD (9) (50/~g/injec- 
tion). Animals were bled 1 wk after the final  immunization, and 
antibody titers were measured  in the ELISA  format. Monkeys  were 
immunized with Pfs25-B and MF59, or MF59 alone  using the same 
protocol, except that injections were carried out at 4-wk intervals. 
Immunized and control animals were bled at 2-wk intervals for 
ELISAs, and transmission-blocking activities were measured at 
weeks 12 and 22. 
ELISA.  ELISAs  were performed as described previously (7). 
Titers were calculated  at 0.2 absorbance units using a Vm~ micro- 
titer plate reader (Molecular  Devices, Palo Alto, CA) programmed 
to read at 650 mm with subtraction of the 490-nm reading. 
Antibodies.  mAb 4B7 was produced by fusion of spleen cells 
from a BALB/c mouse immunized twice with recombinant vac- 
cinia virus that were expressing Pfs25, and boosted with whole 
P.faki~rum gametes. Supernatants from the fusion were screened 
for specificity  to Pfs25 by immunoblot of reduced Pfs25-B (D. C. 
Kaslow, unpublished observations). Antisera P7 was produced by 
pooling sera from mice immunized individually  with the peptides 
SLKCLKENETCKAVD, LKENETCKAVDGIYK, KAVDGIY- 
KCDCKDGF, GIYKCDCKDGFIIDN, and DCKDGFIIDNESSI, 
which are derived from the fourth EGF-like domain of Pfs25. 
Transmission-blocking  Assays.  Murine or monkey sera were as- 
sayed  for transmission-blocking  activity as described  previously  (2). 
Briefly, sera or mAb ascites fluid were mixed in a 1:1 ratio with 
erythrocyte cultures that contained P. fakiparum gametocytes and 
the mixtures were fed to Anophelesfreeborni mosquitoes using a 
membrane feeding apparatus. After 7 d, mosquitoes were dissected 
and examined for the presence of P. faki~rum  oocysts (2). 
Results and Discussion 
We chemically synthesized a gene for Pfs25 that encoded 
amino acids 22-190 of the natural 217-amino acid precursor 
protein (10), and thereby deleted the proposed NH2-terminal 
secretory signal sequence. Also deleted was the hydrophobic 
COOH-terminal region that has been proposed to serve as 
a  signal for attachment of a glycosylphosphatidyl-inositol 
membrane anchor (10, 11). Expression and secretion from 
yeast of this Pfs25 extracellular domain was achieved by fu- 
sion of the synthetic gene to DNA sequences encoding the 
yeast ol factor pheromone secretory signal/leader sequence 
(8). Transcription  was driven by the glucose-regulated  alcohol 
dehydrogenase 2/glyceraldehyde-3-phosphate dehydrogenase 
(ADH2/GAPDH) hybrid promoter described previously (12). 
A second gene was also constructed, in which the three re- 
maining N-linked glycosylation  sites at amino acid positions 
112, 165,  and 187 of the encoded protein (Fig.  1 A) were 
removed by Asn-*Ala mutation and introduction of a termi- 
nation codon after Glu188. The removal of glycosylation sites 
allowed the secretion of a homogeneous product that also 
contained all four epidermal growth factor (EGF)-like repeats 
described previously for Pfs25 (Fig.  1 A) (10). This protein, 
designated Pfs25-B,  was selected  for further study. 
The secreted protein was purified (Fig. 1 B), and analyzed 
by immunoblotting using rabbit polyclonal antisera to Pfs25 
or with the mAb 1C7 (10), a transmission-blocking mAb 
that had been shown previously to recognize natural Pfs25 
only under nonreducing conditions. The purified protein was 
used to immunize mice and Aotus trivirgatus monkeys with 
the muramyl tripeptide (MTP) adjuvant MF59, an adjuvant 
that has been used previously to elicit high antibody titers 
in rodents and goats with other recombinant malaria pro- 
teins (7), and has also been demonstrated to be safe and e~ca- 
dous in humans when used in conjunction with a yeast-derived 
HIV-1  envelope  protein (13). 
Humoral immune responses  elicited in mice with both 
Freund's adjuvant and MF59 (Table 1), and in monkeys with 
MF59 (Fig.  2),  were measured by ELISA. Also shown are 
the reactivities of antisera raised  with recombinant Pfs25 
against various control recombinant proteins from yeast. These 
include human superoxide dismutase (hSOD) (9), a circum- 
sporozoite (CS) protein from P. falciparum  (falc 2.3) (7), and 
Figure 1.  (A) Schematic  representa- 
tions of the natural 217-amino acid 
Pfs25 protein and the yeast recom- 
binant Pfs25-B. Shown are the four 
regions with sequence homology  to 
EGF (hatched and arr0wed), potential 
N-linked  glycosyhtion  sites  (0), a puta- 
tive signal peptide sequence (Sig), and 
consensus  signal  peptidase  cleavage  site 
(,L). Also  shown  is a hydrophobic  trans- 
membrane domain  (TMD) that serves 
as an attachment signal for a glyco- 
sylphosphatidyl-inositol  anchor  (8, 9). 
Sites within Pfs25-B that were muta- 
genized  to remow  glycosyhtion  sites  are 
marked  at Asn112  and Asn165. (B) Ex- 
pression, secretion,  and purification  of  Pfs25-B  from  yeast.  Molecular  mass markers are in kilodaltons  (Bio-Rad  Laboratories)  (Lane  M); TCA precipitate 
of media  from  recombinant  yeast  cells transformed  with the plasmid  pBS24-Pfs25-B (lane I); pooled  Pfs25-B  fractions  from  chromatography  on A-Seph- 
arose Fast Flow (Pharmacia Fine Chemicals) (lane 2); pooled Pfs25-B fractions  from a further purification  step on Sephacryl S-100 HR (Pharmacia 
Fine Chemicals) (lane 3). Proteins were fractionated  by 15% SDS-PAGE in the presence of 2-ME. 
1204  Transmission-blocking  Malaria Vaccine Table  1.  Antibody  Titers Developed in Mice by Immunization with Recombinant Pfs2S-B and either Freunds (FCA/FIA) 
or MF59 Adjuvants 
Assay protein 
Antigen  Adjuvant  Pfs 25B  Falc 2.3  hEGF  hSOD 
Pfs25-B  FCA/FIA  42,000  <100  <100  <100 
Pfs25-B  MF59  31,625  <100  <100  <100 
Falc 2.3  MF59  <100  20,200  <100  ND 
hEGF  MF59  <100  <100  9,100  ND 
hSOD  MF59  <100  ND  <100  18,750 
human EGF (8, 14). In addition, sera from each immunized 
monkey (12-wk time point) reacted with native Pfs25 on non- 
reducing immunoblots (Fig.  3 A). 
The ability of sera to block the formation of oocysts in 
P. fakiparum  gametocyte-fed mosquitoes was determined as 
described previously (2), and the results are shown in Table 
2 A.  Clearly,  murine antisera  against Pfs25-B from either 
Freund's or MF59-adjuvanted mice were able to dramatically 
reduce or even abolish the sexual development of the parasite 
within the mosquito midgut. Only one oocyst was detected 
in 37 mosquitoes dissected from the immune sera groups, 
whereas all 16 control, preimmune sera-fed mosquitoes de- 
veloped  oocysts,  with  an  average  number  of eight  per 
mosquito. This is comparable with results obtained using the 
transmission-blocking mAb 1D3.  This mAb, at a dilution 
of 1:2 of ascites fluid, fully blocked oocyst development in 
all 16 mosquitoes tested (Table 2 A). Similarly, sera from two 
A.  trivigatus monkeys were capable of blocking completely 
the development of oocysts in mosquitoes after immuniza- 
tion with Pfs25-B. This transmission-blocking activity per- 
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Figure 2.  Antibody titers of Aotus monkeys immunized with Pfs25-B 
and MTP-MF59 adjuvant. Monkeys were injected intramuscularly with 
three 100-/~g doses of Pfs25-B in MF59 (7) at four weekly intervals (~). 
Titers were measured by ELISA every 2 wk, and sera taken at weeks 0, 
12, and 22 were used for mosquito feeding experiments (Table 2 B). 
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sisted for nearly 4 mo in one monkey and ;>6 mo in the other 
(Table 2 B). 
Conformational integrity of Pfs25 has been shown to be 
extremely important for recognition by mAbs that block trans- 
mission. Furthermore, linear or improperly folded epitopes 
of Pfi25 have not been used successfiflly  to elicit transmission- 
blocking immunity. Expression of the related six-cysteine- 
containing hEGF in this yeast system resulted in a correctly 
folded and disulfide-linked polypeptide (14). It was, there- 
fore, somewhat surprising that the conformation-dependent 
neutralizing mAbs 1C7,  1I)2, and 1193, which are known 
to react  with the same epitope of Pfs25,  did not react  as 
strongly with the secreted recombinant Pfs25-B as they did 
with native Pfs25 on nonreducing SDS-PAGE immunoblots 
(Fig. 3 C). As the epitopes recognized by these mAbs are 
destroyed by reduction, but not by SDS, high or low salt 
concentrations, or extremes of pH (I. A. Quakyi and D. C. 
Kaslow, unpublished observations), reactivity of mAbs 1C7 
and 1D2 by immunoblot with recombinant Pfs25 is a sensi- 
tive assay for proper disulfide bond formation at or about 
the mAb epitope, mAb 1C7 showed dear reactivity with 
Pfs25-B under nonreducing conditions (Fig. 3 B). In quan- 
titative studies, however,  mAbs 1D2 and 1C7 were found 
to show markedly reduced reactivities  with Pfs25-B when 
compared with native Pfs25. For example, we could demon- 
strate extensive reactivity of mAb 1D2 with native Pfs25, 
which was isolated from 5  x  106 parasites, under conditions 
where no reactivity could be observed with 10/~g of Pfs25-B 
(Fig. 3 C). A typical yield of native Pfs25 has been shown 
to correspond to ,,o10 #g/109 parasites (10). This very weak 
reactivity of mAb 1/)2 with secreted Pfs25-B indicates that 
this particular transmission-blocking epitope is not completely 
recreated in the recombinant protein. Removal of potential 
N-linked glycosylation sites, or lack of a glycosylphosphatidyl- 
inositol anchor, could explain these findings. A more likely 
explanation, however, is improper disulfide bond formation. 
The disulfide bond structure of the secreted Pfs25-B was ex- 
amined using two other immunological  reagents. P7, an an- 
tisera made to a mixture of synthetic peptides from the fourth 
EGF-like domain of Pfs25, does not recognize native Pfi25. 
P7 only recognizes fully reduced Pfs25, and thus serves as Figure 3.  Immtmoblot analysis  of naive and recombinant 
Pfs25. (A) Native Pfs25 (Triton X-100 extract from 106 
5-h zygotes per lane) were fractionated by 4-20% SDS- 
PAGE under nonreducing conditions, and electroblotted 
to nitrocellulose (2). Reactivity of Pfs25 with pooled Aotus 
monkey prebleed  sera (lane 1), mAb 1D2 (lane 2), im- 
munized monkeys  A142 and A108 (lanes 3 and 4), and 
control monkeys All and 1129 (lanes 5 and 6). (/3) Reac- 
tivity of recombinant Pfs25-B with a control mAb against 
Pgs25,  the P. gallinaceum homologue of Pfs25 (lane  I), 
and with mAb 1C7 (lane 2). (C) Pfs25-B (10 #g per lane; 
lanes 2, 4, and 5) and native Pfs25 (Triton X-100 extract 
from 5  x  106 5-h zygotes per lane; lanes 1 and 3) were 
fractionated similarly, in the presence (reduced) or absence 
(nonreduced) of 5 % 2-ME and electroblotted to nitrocel- 
lulose (2). Binding of a 1:200 dilution of mAb 1D2 (lanes 
I  and 2), mAb 4B7 (lanes 3 and 4), or antisera P7 (lane 
5). In all cases, electroblotted proteins were detected by 
alkaline phosphatase-labeled  goat anti-mouse sera (Pico- 
Blue;  Stratagene).  MW,  prestained  protein markers  in 
kilodaltons (Bethesda Research  Laboratories). 
an assay for the complete absence of disulfide bonds (I.  A. 
Quakyi et al.,  manuscript in preparation). P7 reacts  with 
Pfs25-B on reducing but not on nonreducing SDS-PAGE im- 
munoblots, suggesting that Pfs25-B contains some disulfide 
bonds in the fourth EGF-like  domain, mAb 4B7,  a previ- 
ously undescribed mAb to Pfs25 that reacts quite strongly 
with nonreduced  Pfs25 and weakly with reduced Pfs25, dearly 
reacts  with  nonreduced Pfs25-B. The reactivity increased 
markedly upon reduction of Pfs25-B. These data suggest that 
the mAb 4B7 epitope is improperly formed in Pfs25-B, and 
further that the decreased reactivity with Pfs25-B, as com- 
pared with parasite-produced Pfs25, is not a result of post- 
translational modification. Thus, although Pfs25-B appears 
to possess only partial conformational integrity, the yeast- 
derived product was still fully capable of inducing transmission- 
blocking immunity in both mice and monkeys. 
It has been proposed that the homology of Pfs25 to EGF 
might give rise to an autoimmune response in individuals 
immunized with Pfs25.  Our data indicate that this is not 
likely to be the case. First, transmission-blocking antisera did 
not recognize recombinant hEGF in ELISA (Table 1), nor 
did antisera to hEGF recognize Psf25-B in such an assay (Table 
1). Second, antisera generated against Pfs25-B did not block 
EGF activity in either cell proliferation (14) or receptor-binding 
(15) assay systems (data not shown). We anticipate that cross- 
reactivity of antibodies to Pfs25 with hEGF, as well as other 
members of the polypeptide family that contain EGF-like 
motifs, may not be a complication of this vaccination strategy. 
Several recombinant DNA-derived antigens or synthetic 
peptides of malaria parasites have been shown to be only weakly 
immunogenic  in humans (16, 17). Since Pfs25 is not expressed 
at the gametocyte stage, but appears only during sexual de- 
velopment in the mosquito, and has, therefore, not been sub- 
jected to immune pressure in the human host, it might be 
anticipated that the immunogenicity of Pfs25-B in humans 
will closely parallel that observed in experimental animals. 
Furthermore, transmission-blocking immunity elicited in both 
mice and monkeys was observed with MTP-MF59, an adju- 
vant that has been shown previously to be safe and effica- 
cious in humans (13). These studies suggest that recombinant 
DNA-derived Pfs25 is a promising candidate for the study 
of transmission-blocking immunity against P. falciparum in 
humans. 
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1206  Transmission-blocking Malaria Vaccine Table  2.  Inhibition of Oocyst Development by Sera from Immunized Animals 
Mean oocyst numbers  Infectivity  Mosq.  infected/ 
Sample  (range)  percent  of control  mosq.  dissected 
A.  Pooled (preimmune)  7.6  100%  16/16 
(1-22) 
Pfs25-B  (CFA/IFA)  0  <1%  1/19 
(o-i) 
Pfs25-B  (MF59)  0  0%  0/18 
(0) 
Falc 2.3  (MF59)  4.2  55%  17/18 
(0o13) 
mAb 1D3  0  0%  0/16 
(0) 
B.  A108 (preimmune)  39  100%  20/21 
(0-89) 
A142 (preimmune)  25  100%  21/21 
(5-75) 
A108 (wk  12)  0  <1%  1/24 
(001) 
A142 (wk  12)  0  0%  0/20 
(0) 
A108 (wk 22)  0  0%  0/28 
(0) 
A142 (wk 22)  2.6  10%  15/26 
(0-35) 
mAb 1D2  0  <1%  1/20 
(00i) 
mAb 4B7  0  0%  0/24 
(0) 
(A) Sera from mice immunized with  Pfs25-B or falc 2.3 (Table 1) were assayed for transmission-blocking activity and compared with  the mAb 
1D3. Mosquitoes were fed on either the mouse sera or mAb ascites fluid at a 1:2 dilution of the feed (2, 3). Mosquitoes were dissected after 7-8 d, 
and the numbers of infected mosquitoes and oocysts determined. Infectivity was scored as the number of oocysts found in the sample divided by 
the number found in the pooled prebleed control ( x 100%). (/3) The ability of sera from two immunized Aotus monkeys to block oocyst development 
was measured as above. Here, prebleed sera from each monkey (numbers A108 and A142) were used as controls. Transmission-blocking  activities 
were measured at 12 and 22 wk. In this experiment, mAbs 1D2 and 4B7 were also shown to block oocyst appearance at a 1:2 dilution, whereas 
sera from two monkeys that were injected with  MF59 alone failed to inhibit oocyst development at any of the bleeds assayed (not shown). 
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